According to the article 228 of the Spanish Securities Market Act, the following **RELEVANT FACT** is hereby reported:

“On the date hereof, Pharma Mar, S.A. (“Pharma Mar”) has completed the sale of its subsidiary Xylazel, S.A. (“Xylazel”), a company dedicated to the manufacture, supply and distribution of products for wood and metal treatment, protection and decoration, special paintings and similar products, as well as other products for the construction industry.

The buyer, Akzo Nobel Coatings, S.L. has acquired 100% of the shares, which represent the whole share capital of Xylazel, for a total cash amount of EUR 21.8 million, calculated once adjusted cash and debt.

Said transaction will result on a net gain of approximately EUR 16.6 million as regards Pharma Mar’s individual accounts, and a positive impact on the Consolidated income statement of the Group of approximately EUR 10.3 million.

With this transaction, Pharma Mar takes another step forward regarding its strategy after the merger with Zeltia, S.A. (relevant fact of 30 October 2015, registered under no. 230,415), thus focusing on the pharmaceutical sector.”